Related Experiment Video
Updated: Aug 30, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Pharmacogenetic candidate genes for melanoma
Christopher Hull1, April Larson, Sancy Leachman
1University of Utah School of Medicine. sancy.leachman@hci.utah.edu
Abstract:
The incidence of melanoma is rising at an alarming rate and has become an important public health concern. If detected early, melanoma carries an excellent prognosis after appropriate surgical resection. Unfortunately, advanced melanoma has a poor prognosis and is notoriously resistant to radiation and chemotherapy. The relative resistance of melanoma to a wide-range of chemotherapeutic agents and high toxicity of current therapies has prompted a search for effective alternative treatments that would improve prognosis and limit side effects. Advances in molecular genetics are revealing in increasing detail the mechanisms responsible for the development of melanoma. Hopefully, elucidation of these pathways will provide a means of screening high-risk individuals and allow new drug development for prevention and treatment by identification of specific pharmacological targets. This review will summarize the genetics of melanoma with the goal of providing insights into potential pharmacogenetic candidate genes.
Insights
Melanoma incidence is increasing, posing a public health challenge. Understanding melanoma genetics may lead to targeted treatments and improved patient outcomes.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Melanoma incidence is rising globally, representing a significant public health concern.
- Early-stage melanoma has a good prognosis, but advanced melanoma is resistant to conventional treatments.
- Current therapies for advanced melanoma have limited efficacy and significant toxicity, necessitating alternative approaches.
Purpose of the Study:
- To review the current understanding of melanoma genetics.
- To identify potential pharmacogenetic targets for novel melanoma therapies.
- To provide insights into the molecular mechanisms underlying melanoma development.
Main Methods:
- Literature review of studies on melanoma genetics and molecular pathways.
- Analysis of genetic alterations associated with melanoma development and progression.
- Identification of potential drug targets based on genetic insights.
Main Results:
- Advances in molecular genetics are uncovering detailed mechanisms of melanoma development.
- Specific genetic pathways are implicated in melanoma pathogenesis.
- Elucidation of these pathways offers opportunities for targeted drug development.
Conclusions:
- Understanding melanoma genetics is crucial for developing effective prevention and treatment strategies.
- Pharmacogenetic targets identified through genetic research hold promise for improving melanoma patient outcomes.
- Further research into melanoma genetics can lead to personalized medicine approaches.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants

